ASP Isotopes’ (ASPI) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of ASP Isotopes (NASDAQ:ASPI) in a report issued on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $11.00 price objective on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Stock Performance

Shares of ASPI opened at $5.11 on Tuesday. The company has a 50-day simple moving average of $5.07 and a 200-day simple moving average of $6.77. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $643.35 million, a PE ratio of -2.39 and a beta of 3.59. ASP Isotopes has a 52-week low of $3.92 and a 52-week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.70). The company had revenue of $33.32 million during the quarter, compared to analysts’ expectations of $2.03 million. ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 307.82%. Equities research analysts predict that ASP Isotopes will post -0.24 earnings per share for the current fiscal year.

Insider Activity

In other ASP Isotopes news, COO Robert Ainscow sold 25,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $4.51, for a total transaction of $112,750.00. Following the completion of the transaction, the chief operating officer directly owned 1,512,817 shares in the company, valued at approximately $6,822,804.67. This trade represents a 1.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ASP Isotopes

Several hedge funds have recently modified their holdings of ASPI. Quantbot Technologies LP acquired a new stake in shares of ASP Isotopes during the 3rd quarter worth about $34,000. BNP Paribas Financial Markets boosted its stake in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after purchasing an additional 2,548 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of ASP Isotopes during the 4th quarter worth about $48,000. Pictet Asset Management Holding SA acquired a new stake in shares of ASP Isotopes during the 4th quarter worth about $61,000. Finally, Close Asset Management Ltd acquired a new stake in shares of ASP Isotopes during the 3rd quarter worth about $72,000. 16.80% of the stock is owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.